DERM Dermira Inc.

27.36
-0.16  -1%
Previous Close 27.52
Open 27.52
Price To book 3.06
Market Cap 1137940020
Shares 41,591,375
Volume 450,238
Short Ratio 11.85
Av. Daily Volume 389,106

SEC filingsSee all SEC filings

  1. 8-K - Current report 171013256
  2. 8-K - Current report 171011621
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011477
  4. 8-K - Current report 17918814
  5. 8-K - Current report 17848659

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third and final trial met primary endpoint - January 19, 2017. sBLA filing announced July 24, 2017.
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3 trial initiation announced January 3, 2017. Data are due 1Q 2018.
Olumacostat glasaretil (DRM01)
Acne
Phase 3 data released June 2016. NDA Filing 2H 2017.
Glycopyrronium tosylate (DRM04)
Primary axillary hyperhidrosis

Latest News

  1. Dermira, Inc. – Value Analysis (NASDAQ:DERM) : September 19, 2017
  2. Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2017
  3. Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
  4. New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
  5. Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
  6. See what the IHS Markit Score report has to say about Dermira Inc.
  7. Is It The Right Time To Buy Dermira Inc (DERM)?
  8. Dermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress
  9. Is Dermira Inc (NASDAQ:DERM)'s Confidence In Lebrikizumab Warranted?
  10. Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
  11. Dermira reports 2Q loss
  12. Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 
  13. Suffering from excessive perspiration? Don't sweat it, we...
  14. UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
  15. ETFs with exposure to Dermira, Inc. : July 24, 2017
  16. Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017
  17. Dermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017

SEC Filings

  1. 8-K - Current report 171013256
  2. 8-K - Current report 171011621
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011477
  4. 8-K - Current report 17918814
  5. 8-K - Current report 17848659
  6. 8-K - Current report 17832356
  7. 8-K - Current report 17826510
  8. 8-K - Current report 17822399
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822195
  10. DEF 14A - Other definitive proxy statements 17795324